SCHEMBL4773468

SCHEMBL4773468

O=C(CN1CCC(Cc2ccc(F)cc2)CC1)Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.56
MEN1 O00255 2/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 1/20 0.54
HTT P42858 4/20 0.53
SMN1; SMN2 Q16637 4/20 0.53
MAPT P10636 3/20 0.53
LMNA P02545 3/20 0.53
GAA P10253 2/20 0.53
USP2 O75604 1/20 0.52
POLB P06746 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
CYP2C19 P33261 1/20 0.52
MCOLN3 Q8TDD5 1/20 0.52
KDM4E B2RXH2 2/20 0.52
THRB P10828 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.52
TSHR P16473 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4579020 0.84 SMN1; SMN2 (0.60) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL4577175 0.83 SMN1; SMN2 (0.59) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
Hydrochloric Acid SCHEMBL4577907 0.82 SMN1; SMN2 (0.58) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
Hydrochloric Acid SCHEMBL4577189 0.82 MEN1 (0.57) KMT2AMEN1ALDH1A1SMN1; SMN2LMNA
SCHEMBL4419077 0.81 GRIN1 (0.60) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL4577591 0.80 SMN1; SMN2 (0.66) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL4577637 0.80 CCR3 (0.69) KMT2AMEN1ALDH1A1HTTSMN1; SMN2
SCHEMBL27590226 0.80 CCR3 (0.70) KMT2AMEN1ALDH1A1SMN1; SMN2MAPT
SCHEMBL4777958 0.80 CCR5 (0.49) CYP3A4TSHRCCR3
SCHEMBL4578105 0.80 LMNA (0.58) KMT2AMEN1ALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-1220842-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2002-07-10 EP disclosed
WO-2001025200-A1 CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 KMT2A 2421/4885MEN1 2216/4885ALDH1A1 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.